Journal article
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Abstract
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients …
Authors
Pol JG; Lévesque S; Workenhe ST; Gujar S; Le Boeuf F; Clements DR; Fahrner J-E; Fend L; Bell JC; Mossman KL
Journal
OncoImmunology, Vol. 7, No. 12,
Publisher
Taylor & Francis
Publication Date
December 2, 2018
DOI
10.1080/2162402x.2018.1503032
ISSN
2162-4011